PURPOSE OF REVIEW: To provide an updated literature review highlighting important aspects of cystic fibrosis-related diabetes (CFRD) including epidemiology, pathogenesis, complications, screening, and management. RECENT FINDINGS: Although CFRD continues to be associated with increased rates of mortality in the cystic fibrosis (CF) population, this has improved over the past several years, and the previous sex difference is no longer present. Recent studies support that CFRD is primarily caused by insulin deficiency due to loss of beta cells, which may occur via a number of mechanisms including oxidative stress. Aggressive screening programs with oral-glucose tolerance testing and early treatment with insulin for patients with CFRD with or without fasting hyperglycemia have led to improvements in nutritional states and lung function. Oral agents do not appear to be effective in CFRD. SUMMARY: CFRD is the most common comorbidity in the CF population and is associated with microvascular complications and protein catabolism leading to worse health outcomes. Recognition of glycemic abnormalities through aggressive screening has led to improvements in nutritional status, pulmonary function, and mortality rates.
PURPOSE OF REVIEW: To provide an updated literature review highlighting important aspects of cystic fibrosis-related diabetes (CFRD) including epidemiology, pathogenesis, complications, screening, and management. RECENT FINDINGS: Although CFRD continues to be associated with increased rates of mortality in the cystic fibrosis (CF) population, this has improved over the past several years, and the previous sex difference is no longer present. Recent studies support that CFRD is primarily caused by insulin deficiency due to loss of beta cells, which may occur via a number of mechanisms including oxidative stress. Aggressive screening programs with oral-glucose tolerance testing and early treatment with insulin for patients with CFRD with or without fasting hyperglycemia have led to improvements in nutritional states and lung function. Oral agents do not appear to be effective in CFRD. SUMMARY: CFRD is the most common comorbidity in the CF population and is associated with microvascular complications and protein catabolism leading to worse health outcomes. Recognition of glycemic abnormalities through aggressive screening has led to improvements in nutritional status, pulmonary function, and mortality rates.
Authors: T Pincikova; K Nilsson; I E Moen; G Fluge; A Hollsing; P K Knudsen; A Lindblad; L Mared; T Pressler; L Hjelte Journal: Diabetologia Date: 2011-09-07 Impact factor: 10.122
Authors: Neda Rasouli; Stacey Seggelke; Joanna Gibbs; R Matthew Hawkins; Matthew L Casciano; Elizabeth Cohlmia; Jennifer Taylor-Cousar; Cecilia Wang; Rocio Pereira; Elisa Hsia; Boris Draznin Journal: J Diabetes Sci Technol Date: 2012-09-01
Authors: Xingshen Sun; Yaling Yi; Weiliang Xie; Bo Liang; Michael C Winter; Nan He; Xiaoming Liu; Meihui Luo; Yu Yang; Katie Larson Ode; Aliye Uc; Andrew W Norris; John F Engelhardt Journal: Endocrinology Date: 2017-10-01 Impact factor: 4.736
Authors: Aliye Uc; Alicia K Olivier; Michelle A Griffin; David K Meyerholz; Jianrong Yao; Maisam Abu-El-Haija; Katherine M Buchanan; Oriana G Vanegas Calderón; Marwa Abu-El-Haija; Alejandro A Pezzulo; Leah R Reznikov; Mark J Hoegger; Michael V Rector; Lynda S Ostedgaard; Peter J Taft; Nick D Gansemer; Paula S Ludwig; Emma E Hornick; David A Stoltz; Katie L Ode; Michael J Welsh; John F Engelhardt; Andrew W Norris Journal: Clin Sci (Lond) Date: 2015-01 Impact factor: 6.124
Authors: Katja Konrad; Angelika Thon; Maria Fritsch; Elke Fröhlich-Reiterer; Eggert Lilienthal; Stefan A Wudy; Reinhard W Holl Journal: Diabetes Care Date: 2012-12-13 Impact factor: 19.112